A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

NCT06973681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-05-15

No results posted yet for this study

Summary

To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

DRUG

BGM0504

Administered SC

DRUG

BGM0504

Administered SC

DRUG

BGM0504

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-13
Primary Completion
2024-09-13
Completion
2024-09-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06973681 on ClinicalTrials.gov